

# CURRENT VIEW ON PHARMACOTHERAPY OF LOW RESPIRATORY TRACT INFECTIONS: THE PLACE FOR MACROLIDES

**T. O. Pertseva, T. V. Kireieva, M. A. Krychtina**

## *Abstract*

The paper presents an analysis of the current literature on the practice of macrolides use in patients with lower respiratory tract infections (LRTI). The various regimens and doses of macrolides in patients with chronic obstructive pulmonary disease (COPD) exacerbation and remission, community-acquired pneumonia (CAP), cystic fibrosis (CF) and bronchiectasis (BE) were analyzed.

There was reviewed over 50 studies which examined not only antibacterial effects of macrolides, but pleiotropic, antiviral, virulence modifying, biofilm lysis, and immunomodulatory effects as well.

The survey included data from meta-analyzes of the studies on macrolides in COPD, CF, BE and CAP for the period from 1999 to 2014 years.

The findings confirmed high effectiveness of macrolides in management of LRTI. The use of this group of antibiotics for prophylaxis is not justified due to high risk of microbial resistance.

**Key words:** macrolides, low respiratory tract infections.

**Ukr. Pulmonol. J. 2015; 3:49–55.**

*Tatyana A. Pertseva*

*Dnipropetrovsk State Medical Academy*

*Head of the department of faculty therapy and endocrinology*

*Corresponding member of National Academy*

*of Medical Sciences of Ukraine, professor*

*9, Dzerzhynskiy str., Dnipropetrovsk, 49044, Ukraine*

*Tel.: 380567135257, dsma@dsma.dp.ua*